Abbott Laboratories is writing a hefty check to settle a years-long controversy. The company has agreed to pay more than $384 million to resolve U.S. Justice Department allegations that it knowingly produced infant formula in conditions that posed a substantial contamination risk — and then sold those products to federally and state-funded programs like USDA and Medicaid without proper testing or regulatory disclosure.

The settlement stems from a 2022 recall of Abbott baby formula after traces of potentially deadly bacteria were found at its Sturgis, Michigan plant. The recall, combined with pandemic-era supply chain disruptions, triggered a nationwide infant formula shortage. Abbott maintains that no unopened, distributed products ever tested positive for the bacteria, and the company did not admit liability as part of the deal. A related criminal investigation has also been closed.

By the Numbers:

• $384 million+ — total settlement amount
• 2022 — year of the infant formula recall and Michigan plant closure
• 2 plants implicated — Sturgis, Michigan and Casa Grande, Arizona
• Payments came from USDA and state Medicaid funds used to subsidize formula for eligible families

Why it matters: This settlement highlights critical gaps in infant food safety oversight and the real-world consequences when manufacturers fail to self-report contamination risks. For pediatric and public health providers, it underscores the importance of robust supply chain transparency — especially for vulnerable populations like infants who depend on formula as their sole nutrition source.